Dianeal Low Calcium
"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Dianeal Low Calcium
Dianeal Low Calcium Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Dianeal Low Calcium (low calcium peritoneal dialysis solutions) is used in chronic renal failure patients being maintained on peritoneal dialysis. Common side effects include abdominal pain, bleeding, peritonitis, infection under the skin around a chronic peritoneal catheter, catheter blockage, difficulty in fluid removal, electrolyte and fluid imbalances, high or low blood volume, high or low blood pressure, disequilibrium syndrome, and muscle cramping.
Dosing of Dianeal Low Calcium is individualized. The mode of therapy (Intermittent Peritoneal Dialysis [IPD], Continuous Ambulatory Peritoneal Dialysis [CAPD], or Continuous Cyclic Peritoneal Dialysis [CCPD]), frequency of treatment, formulation, exchange volume, duration of dwell, and length of dialysis is selected by a physician. Dianeal Low Calcium may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Dianeal Low Calcium should be administered only if prescribed. Consult your doctor before breastfeeding.
Our Dianeal Low Calcium (low calcium peritoneal dialysis solutions) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Dianeal Low Calcium FDA Prescribing Information: Side Effects
Adverse reactions to peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around a chronic peritoneal catheter, catheter blockage, difficulty in fluid removal, and ileus are among the complications of the procedure. Solution related adverse reactions may include electrolyte and fluid imbalances, hypovolemia, hypervolemia, hypertension, hypotension, disequilibrium syndrome, and muscle cramping.
When prescribing the solution to be used for an individual patient, consideration should be given to the potential interaction between the dialysis treatment and therapy directed at other existing illnesses. For example, rapid potassium removal may create arrhythmias in cardiac patients using digitalis or similar drugs; digitalis toxicity may be masked by elevated potassium or magnesium, or by hypocalcemia. Correction of electrolytes by dialysis may precipitate signs and symptoms of digitalis excess. Conversely, toxicity may occur at suboptimal dosages of digitalis if potassium is low or calcium high. Azotemic diabetics require careful monitoring of insulin requirements during and following dialysis with dextrose containing solutions.
Read the entire FDA prescribing information for Dianeal Low Calcium (Low Calcium Peritoneal Dialysis Solutions)
Additional Dianeal Low Calcium Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.